Drug Database · Clinicians

Gemcitabine

Brands (63) Bagogem, Bligem, Celzar…Show all

Antineoplastic (pyrimidine analogue); Antineoplastic agent (pyrimidine analogue); and others PH FDA category

Rx · Prescription drug87 PH productsPNF-listedVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 44bcc16c-341d-49e8-a1c6-95d084667aca, version date August 20, 2026 (gemcitabine · Sagent Pharmaceuticals). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
  • in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.
  • in combination with cisplatin, for the treatment of non-small cell lung cancer.
  • as a single agent for the treatment of pancreatic cancer.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Gemcitabine for Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. (1.1) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.

(1.2) in combination with cisplatin, for the treatment of non-small cell lung cancer. (1.3) as a single agent for the treatment of pancreatic cancer. (1.4) 1.1 Ovarian Cancer Gemcitabine for Injection, USP in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. 1.2 Breast Cancer Gemcitabine for Injection, USP in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemcitabine for Injection, USP in combination with cisplatin is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC). 1.4 Pancreatic Cancer Gemcitabine for Injection, USP is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas.

Gemcitabine for Injection, USP is indicated for patients previously treated with fluorouracil.

Contraindications

4 CONTRAINDICATIONS Gemcitabine for Injection, USP is contraindicated in patients with a known hypersensitivity to gemcitabine. Reactions include anaphylaxis [see Adverse Reactions (6.1)]. Patients with a known hypersensitivity to gemcitabine. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Gemcitabine for Injection is for intravenous use only. Ovarian Cancer: 1000 mg/m 2 over 30 minutes on Days 1 and 8 of each 21-day cycle. (2.1)
  • Breast Cancer: 1250 mg/m 2 over 30 minutes on Days 1 and 8 of each 21-day cycle. (2.2)
  • Non-Small Cell Lung Cancer: 1000 mg/m 2 over 30 minutes on Days 1, 8, and 15 of each 28-day cycle or 1250 mg/m 2 over 30 minutes on Days 1 and 8 of each 21-day cycle. (2.3)
  • Pancreatic Cancer: 1000 mg/m 2 over 30 minutes once weekly for the first 7 weeks, then one week rest, then once weekly for 3 weeks of each 28-day cycle. (2.4)
2.1 Ovarian Cancer Recommended Dose and Schedule

2.1 Ovarian Cancer Recommended Dose and Schedule The recommended dosage of Gemcitabine for Injection, USP is 1000 mg/m 2 intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle in combination with carboplatin AUC 4 administered intravenously on Day 1 after Gemcitabine for Injection, USP administration. Refer to carboplatin prescribing information for additional information.

Dosage Modifications Recommended Gemcitabine for Injection, USP dosage modifications for myelosuppression are described in Tables 1 and 2 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)]. Table 1: Recommended Dosage Modifications for Gemcitabine for Injection, USP for Myelosuppression on Day of Treatment in Ovarian Cancer Treatment Day Absolute Neutrophil Count (x 10 6 /L) Platelet Count (x 10 6 /L) Dosage Modification Day 1 Greater than or equal to 1500 And Greater than or equal to 100,000 None Less than 1500 Or Less than 100,000 Delay Treatment Cycle Day 8 Greater than or equal to 1500 And Greater than or equal to 100,000 None 1000 to 1499 Or 75,000 to 99,999 50% of full dose Less than 1000 Or Less than 75,000 Hold Table 2: Recommended Dosage Modifications for Gemcitabine for Injection, USP for Myelosuppression in Previous Cycle in Ovarian Cancer Occurrence Myelosuppression During Treatment Cycle Dosage Modification Initial Occurrence Absolute neutrophil count less than 500 x 10 6 /L for more than 5 days or Absolute neutrophil count less than 100 x 10 6 /L for more than 3 days or Febrile neutropenia or Platelets less than 25,000x10 6 /L or Cycle delay for more than one week due to toxicity Permanently reduce Gemcitabine for Injection, USP to 800 mg/m 2 on Days 1 and 8 Subsequent Occurrence If any of the above toxicities occur after the initial dose reduction: Permanently reduce Gemcitabine for Injection, USP to 800 mg/m 2 on Day 1 only

2.2 Breast Cancer Recommended Dose and Schedule

2.2 Breast Cancer Recommended Dose and Schedule The recommended dosage of Gemcitabine for Injection, USP is 1250 mg/m 2 intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle in combination with paclitaxel 175 mg/m 2 administered as a 3-hour intravenous infusion on Day 1 before Gemcitabine for Injection, USP administration. Refer to paclitaxel prescribing information for additional information.

Dosage Modifications Recommended Gemcitabine for Injection, USP dosage modifications for myelosuppression are described in Table 3 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)]. Table 3: Recommended Dosage Modifications for Gemcitabine for Injection, USP for Myelosuppression on Day of Treatment in Breast Cancer Treatment Day Absolute Neutrophil Count (x 10 6 /L) Platelet Count (x 10 6 /L) Dosage Modification Day 1 Greater than or equal to 1500 And Greater than or equal to 100,000 None Less than 1500 Or Less than 100,000 Hold Day 8 Greater than or equal to 1200 And Greater than 75,000 None 1000 to 1199 Or 50,000 to 75,000 75% of full dose 700 to 999 And Greater than or equal to 50,000 50% of full dose Less than 700 Or Less than 50,000 Hold

2.3 Non-Small Cell Lung Cancer Recommended Dose and Schedule 28

2.3 Non-Small Cell Lung Cancer Recommended Dose and Schedule 28-day schedule The recommended dosage of Gemcitabine for Injection, USP is 1000 mg/m 2 intravenously over 30 minutes on Days 1, 8, and 15 of each 28-day cycle in combination with cisplatin 100 mg/m 2 administered intravenously on Day 1 after Gemcitabine for Injection, USP administration. 21-day schedule The recommended dosage of Gemcitabine for Injection, USP is 1250 mg/m 2 intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle in combination with cisplatin 100 mg/m 2 administered intravenously on Day 1 after Gemcitabine for Injection, USP administration. Refer to cisplatin prescribing information for additional information.

Dosage Modifications Recommended dosage modifications for Gemcitabine for Injection, USP myelosuppression are described in Table 4 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)].

2.4 Pancreatic Cancer Recommended Dose and Schedule

2.4 Pancreatic Cancer Recommended Dose and Schedule The recommended dosage of Gemcitabine for Injection, USP is 1000 mg/m 2 intravenously over 30 minutes. The recommended treatment schedule is as follows: Weeks 1 to 8: weekly dosing for the first 7 weeks followed by one week rest. After week 8: weekly dosing on Days 1, 8, and 15 of each 28-day cycle.

Dosage Modifications Recommended dosage modifications for Gemcitabine for Injection, USP for myelosuppression are described in Table 4 [see Warnings and Precautions (5.2)]. Refer to the recommended dosage modifications for non-hematologic adverse reactions [see Dosage and Administration (2.5)]. Table 4: Recommended Dosage Modifications for Gemcitabine for Injection, USP for Myelosuppression in Pancreatic Cancer and Non-Small Cell Lung Cancer Absolute Neutrophil Count (x 10 6 /L) Platelet Count (x 10 6 /L) Dosage Modification Greater than or equal to 1000 And Greater than or equal to 100,000 None 500 to 999 Or 50,000 to 99,999 75% of full dose Less than 500 Or Less than 50,000 Hold

2.5 Dosage Modifications for Non-Hematologic Adverse Reactions

2.5 Dosage Modifications for Non-Hematologic Adverse Reactions Permanently discontinue Gemcitabine for Injection, USP for any of the following: Severe Cutaneous Adverse Reactions (SCARS) [see Warnings and Precautions (5.3)] Unexplained dyspnea or evidence of severe pulmonary toxicity [see Warnings and Precautions (5.4)] Hemolytic uremic syndrome (HUS) or severe renal impairment [see Warnings and Precautions (5.5)] Severe hepatic toxicity [see Warnings and Precautions (5.6)] Capillary leak syndrome (CLS) [see Warnings and Precautions (5.9)] Posterior reversible encephalopathy syndrome (PRES) [see Warnings and Precautions (5.10)] Withhold Gemcitabine for Injection, USP or reduce dose by 50% for other Grade 3 or 4 non-hematological adverse reactions until resolved. No dose modifications are recommended for alopecia, nausea, or vomiting.

2.6 Preparation Gemcitabine for Injection

2.6 Preparation Gemcitabine for Injection, USP vials contain no antimicrobial preservatives and are intended for single use only. Gemcitabine for Injection, USP is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 Exercise caution and wear gloves when preparing Gemcitabine for Injection, USP solutions.

Immediately wash the skin thoroughly or rinse the mucosa with copious amounts of water if Gemcitabine for Injection, USP contacts the skin or mucus membranes. Death has occurred in animal studies due to dermal absorption. Reconstitute the 200 mg vial with 5 mL and the 1 gram vial with 25 mL of 0.9% Sodium Chloride Injection, USP to yield a Gemcitabine for Injection, USP concentration of 38 mg per mL.

Reconstituted Gemcitabine for Injection, USP is a clear, colorless to light straw-colored solution. Visually inspect reconstituted product for particulate matter and discoloration. Discard if particulate matter or discoloration is observed. Withdraw the calculated dose from the vial and discard any unused portion. Prior to administration, dilute the reconstituted solution with 0.9% Sodium Chloride Injection, USP to a minimum final concentration of at least 0.1 mg per mL.

Store Gemcitabine for Injection, USP solutions (reconstituted and diluted) at controlled room temperature of 20° to 25°C (68° to 77°F). Do not refrigerate as crystallization can occur. Discard Gemcitabine for Injection, USP solutions if not used within 24 hours after reconstitution. No incompatibilities have been observed with infusion bottles or polyvinyl chloride bags and administration sets.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (pharmacokinetics)

Patients with Renal Impairment No clinical studies have been conducted with gemcitabine in patients with decreased renal function.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of Gemcitabine for Injection have not been established in pediatric patients. The safety and pharmacokinetics of gemcitabine were evaluated in a trial in pediatric patients with refractory leukemia. The maximum tolerated dose was 10 mg/m 2 /min for 360 minutes weekly for three weeks followed by a one-week rest period.

The safety and activity of Gemcitabine for Injection were evaluated in a trial of pediatric patients with relapsed acute lymphoblastic leukemia (22 patients) and acute myelogenous leukemia (10 patients) at a dose of 10 mg/m 2 /min administered over 360 minutes weekly for three weeks followed by a one-week rest period. Patients with M1 or M2 bone marrow on Day 28 who did not experience unacceptable toxicity were eligible to receive a maximum of one additional four-week course.

Toxicities observed included myelosuppression, febrile neutropenia, increased serum transaminases, nausea, and rash/desquamation. No meaningful clinical activity was observed in this trial.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use In clinical studies which enrolled 979 patients with various malignancies who received single agent Gemcitabine for Injection, no overall differences in safety were observed between patients aged 65 and older and younger patients, with the exception of a higher rate of Grade 3 or 4 thrombocytopenia in older patients as compared to younger patients. In a randomized trial in women with ovarian cancer (Study 1), 175 women received Gemcitabine for Injection with carboplatin, of which 29% were age 65 years or older.

Similar effectiveness was observed between older and younger women. There was significantly higher Grade 3-4 neutropenia in women 65 years of age or older [see Dosage and Administration (2.1)]. Gemcitabine for Injection clearance is affected by age; however, there are no recommended dose adjustments based on patients' age [see Clinical Pharmacology (12.3)].

Administration

2.6 Preparation Gemcitabine for Injection, USP vials contain no antimicrobial preservatives and are intended for single use only. Gemcitabine for Injection, USP is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 Exercise caution and wear gloves when preparing Gemcitabine for Injection, USP solutions. Immediately wash the skin thoroughly or rinse the mucosa with copious amounts of water if Gemcitabine for Injection, USP contacts the skin or mucus membranes. Death has occurred in animal studies due to dermal absorption. Reconstitute the 200 mg vial with 5 mL and the 1 gram vial with 25 mL of 0.9% Sodium Chloride Injection, USP to yield a Gemcitabine for Injection, USP concentration of 38 mg per mL. Reconstituted Gemcitabine for Injection, USP is a clear, colorless to light straw-colored solution. Visually inspect reconstituted product for particulate matter and discoloration. Discard if particulate matter or discoloration is observed. Withdraw the calculated dose from the vial and discard any unused portion. Prior to administration, dilute the reconstituted solution with 0.9% Sodium Chloride Injection, USP to a minimum final concentration of at least 0.1 mg per mL. Store Gemcitabine for Injection, USP solutions (reconstituted and diluted) at controlled room temperature of 20° to 25°C (68° to 77°F). Do not refrigerate as crystallization can occur. Discard Gemcitabine for Injection, USP solutions if not used within 24 hours after reconstitution. No incompatibilities have been observed with infusion bottles or polyvinyl chloride bags and administration sets.

US FDA label

Dosage forms

Philippines

  • Lyophilized powder for injection: 1 g, 2 g, 200 mg
  • Lyophilized powder for iv infusion: 1 g, 200 mg
  • Lyophilized powder for i.v. infusion: 1 g, 200 mg
  • Lyophilized powder for injection for i.v. infusion: 1 g, 200 mg
  • Powder for injection: 1 g
  • ) concentrate for solution for iv infusion: 100 mg/mL (1.5 g/15 mL, 100 mg/mL (2 g/20 mL, 1000 mg/10 mL (1 g/10 mL, 1000 mg/mL (200 mg/2 mL
  • Powder for solution for iv infusion: 1 g, 200 mg
  • Lyophilized powder for iv injection: 1 g, 200 mg
  • Powder for solution for i.v infusion: 1 g, 200 mg
  • Powder for solution for injection: 1 g, 200 mg

and 11 more forms; see the products table.

Registered products in the Philippines

87 products registered with the Food and Drug Administration (FDA) Philippines list Gemcitabine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products87
Philippine FDA-registered products for Gemcitabine
Package insert
AbingemGemcitabine (as Hydrochloride)
1 g Lyophilized Powder for Injection (IV)Type I Clear Glass Vial (Box of 1's)
RxVAT-exempt
Naprod Life Sciences Pvt. Ltd.India
Multicare Pharmaceuticals Phils. Inc.
DRP-10546
Jan 12, 2030
Aletagem-200Gemcitabine (as hydrochloride)
200 mg Powder for Solution for IV Injection10 mL-USP Type I clear glass vial with slotted rubber plug and sealed with blue flip-off seal (Box of 1's)
RxVAT-exempt
ADMAC LIFESCIENCESIndia
AMBICA INTERNATIONAL CORPORATION
DRP-7644
Jan 26, 2028
BagogemGemcitabine (as hydrochloride)
1 g Lyophilized Powder for Solution for IV Infusion50-mL capacity USP Type I Clear glass vial with bromobutyl rubber stopper and red flip-off aluminum seal (Box of 1's)
RxVAT-exempt
Laboratorio Kemex S.A.Argentine Republic
Apolloplus Capital Inc.Trader: Bioprofarma Bago S.A.
DR-XY47158
Apr 22, 2031
BagogemGemcitabine (as hydrochloride)
200 mg Lyophlized Powder Solution for IV Infusion12-mL capacity USP Type I clear glass vial with bromobutyl rubber stopper and white flip-off aluminum seal (Box of 1's)
RxVAT-exempt
Laboratorio Kemex S.A.Argentine Republic
Apolloplus Capital Inc.Trader: Bioprofarma Bago S.A.
DR-XY47157
May 6, 2031
BligemGemcitabine (as hydrochloride)
1 g Lyophilized Powder for Injection (I.V. Infusion)Type I tubular clear glass vial with a grey butyl rubber plug and green colour flip-off seal (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
Bliss Pharma Distribution And Consultancy Corp.
DRP-8997
Jul 29, 2030
BligemGemcitabine (as hydrochloride)
200 mg Lyophilized Powder for Injection (I.V. Infusion)Type I tubular clear glass vial with grey butyl rubber plug and green colour flip-off seal (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
Bliss Pharma Distribution And Consultancy Corp.
DRP-8999
Jul 29, 2030
CelzarGemcitabine (as Hydrochloride)
1g Powder for Solution for I.V. Infusion50 mL Clear USP Type I Tubular Vial Sealed with Grey Colored Bromo-Butyl Rubber Stopper & Red Colored Aluminium Flip-Off Seal (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E Medica, Inc.
DRP-6269
Sep 18, 2030
CelzarGemcitabine (as hydrochloride)
200 mg Powder for Solution for I.V Infusion50 mL Clear USP Type -1 tubular vial sealed with grey colored bromo-butyl rubber stopper & red colored aluminium flip-off seal (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E Medica Inc.
DRP-6270
Sep 18, 2030
CitagemGemcitabine
1 g Lyophilized Powder for I.V. InfusionUSP Type I Clear Glass Vial x 10 mL (Box of 1's)
RxVAT-exempt
Beacon Pharmaceuticals PLCBangladesh
UNILAB, Inc.
DR-XY40335
Nov 23, 2031
CitagemGemcitabine
200 mg Lyophilized Powder for I.V. InfusionUSP Type I Clear Glass Vial x 10 mL (Box of 1's)
RxVAT-exempt
Beacon Pharmaceuticals PLCBangladesh
UNILAB, Inc.
DR-XY40334
Nov 23, 2031
Emcisanz-1000Gemcitabine (As Hydrochloride)
1 g Powder for Solution for I.V. Infusion50 mL USP Type I clear moulded glass vial and sealed with grey bromo butyl rubber plug and blue flip-off seal (Box of of 1's)
RxVAT-exempt
Admac LifesciencesIndia
AGB Pharmaceutical Trading and Consultancy Corporation.Importer: AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-13444
Feb 20, 2028
Emcisanz-200Gemcitabine (As Hydrochloride)
200mg Powder For Solution For IV Infusion10 mL USP Type I clear moulded glass vial and sealed with grey bromo butyl rubber plug and blue flip-off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
AGB Pharmaceutical Trading and CorporationImporter: AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-13445
Feb 20, 2028
GecibixilGemcitabine (as hydrochloride)
1 g Lyophilized Powder for Injection (I.V.)Clear USP Type I Flint glass vial sealed with grey rubber closure, aluminum seal and sky blue flip-off cap x 50 mL (Box of 1's)
RxVAT-exempt
Getwell Pharma India Pvt. Ltd.India
Globo Asiatico Enterprises, Inc.Importer: Ambica International Corporation
DRP-6330-02
Sep 1, 2030
GecitaGemcitabine (As Hydrochloride)
1 g Lyophilized Powder for I.V. InfusionUSP Type 1 clear moulded glass vial with rubber bromo butyl plug and blue color flip off seal (Box of l's)
RxVAT-exempt
ADMAC LifesciencesIndia
Suhitas Pharmaceuticals Inc.
DRP-12400
Aug 2, 2027
Gecita-200Gemcitabine (as hydrochloride)
200 mg Lyophilized Powder for I.V. InfusionUSP Type 1 clear moulded glass vial with rubber bromo butyl plug and blue flip off seal (Box of l’s)
RxVAT-exempt
ADMAC LifesciencesIndia
Suhitas Pharmaceuticals Inc.
DRP-12401
Aug 2, 2027
Gem Pan 1000Gemcitabine (As Hydrochloride)
1000 mg Powder for IV Infusion50 mL-capacity USP Type I Tubular Glass Vial with gray bromobutyl rubber stopper and red aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Panacea Biotec Ltd.India
Medinova Pharmaceutical Inc.
DRP-13998
Jun 1, 2028
Gem Pan 200Gemcitabine (As Hydrochloride)
200 mg Lyophilized Powder for IV Infusion10 mL USP Type-1 Flint Fiolax Tubular Glass vial with flat bottom stoppered with 20 mm Single Leg Lyo Grey Bromobutyl Rubber stopper sealed with 20 mm Aluminium Flip-off seal. Each individual vial is packed in mono carton. Each carton contains one prescribing information leaflet.
RxVAT-exempt
Panacea Biotec Ltd.India
Medinova Pharmaceutical Inc.
DRP-13999
Jun 1, 2028
Gemaccord 1000Gemcitabine (As Hydrochloride)
1000mg/10mL (1g/10mL) Concentrate for Solution for IV InfusionType I Clear Glass Vial x 20 mL with royal blue flip-off seal (Box of l's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Importer: Accord Healthcare Limited-Philippine Branch Office
DRP-11674
Apr 13, 2027
Gemaccord 1500Gemcitabine (As Hydrochloride)
100mg/mL (1.5g/15mL) Concentrate for Solution for IV InfusionType I Clear Glass Vial x 15 mL with red flip-off seal (Box of l's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Importer: Accord Healthcare Limited-Philippine Branch Office
DRP-11675
Apr 13, 2027
Gemaccord 200Gemcitabine (As Hydrochloride)
1000mg/mL (200mg/2mL) Concentrate for Solution for IV InfusionType I Clear Glass Vial x 2 mL with yellow flip-off seal (Box of l's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Importer: Accord Healthcare Limited-Philippine Branch Office
DRP-11673
Apr 13, 2027
Gemaccord 2000Gemcitabine (As Hydrochloride)
100mg/mL (2g/20mL) Concentrate for Solution for IV InfusionType I Clear Glass Vial x 20mL with violet flip-off seal (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Importer: Accord Healthcare Limited-Philippine Branch Office
DRP-11676
Apr 13, 2027
GeMalayaGemcitabine (as hydrochloride)
1 g Lyophilized Powder for Injection (IV)50 mL-capacity USP Type I clear glass vial with rubber stopper and aluminum green flip-off seal (Box of 1’s)
RxVAT-exempt
Venus Remedies, LimitedIndia
Getmeds Philippines Inc.Importer: 2MG Incorporated
DRP-15465-01
Jul 11, 2029
GembioGemcitabine (as hydrochloride)
1 g Lyophilized Powder for IV InfusionType I Clear Glass Vial (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals Ltd.India
Endure Medical, Inc.Importer: Singapore Genebio, Inc.
DRP-9735
Sep 19, 2030
GembioGemcitabine (as hydrochloride)
200 mg Lyophilized Powder for IV InfusionType I Clear Glass Vial (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Endure Medical, IncImporter: Singapore Genebio, Inc.
DRP-9734
Sep 19, 2030
GemcidexGemcitabine (as hydrochloride)
1 g Lyophilized Powder for IV Infusion50 mL Capacity USP Type I Tubular Glass Vial with gray bromobutyl rubber stopper and red aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Panacea Biotec Pharma LimitedIndia
JC 28 Pharmaceutical Products WholesalingImporter: Medinova Pharmaceutical Inc.
DRP-13998-01
Jun 1, 2028
GemcifarGemcitabine (as hydrochloride)
1 g Lyophilized Powder for IV Injection50 mL USP Type I Clear Colorless Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Seal with Purple Flip-off Cap (Box of 1's)
RxVAT-exempt
Eskayef Pharmaceuticals Limited -Bangladesh
Pharmakon Biotec Inc.
DRP-14638
Nov 9, 2028
GemcifarGemcitabine (as hydrochloride)
200 mg Lyophilized Powder for IV Injection15 mL USP Type I Clear Colorless Glass Vial with. Grey Bromobutyl Rubber Stopper and Aluminum Seal with Purple Flip-off Cap (Box of 1's)
RxVAT-exempt
Eskayef Pharmaceuticals LimitedBangladesh
Pharmakon Biotec Inc.
DRP-14639
Nov 9, 2028
GemcilexGemcitabine
1 g Powder for Injection (IV)USP Type I colorless glass vials sealed with gray bromobutyl rubber stopper and aluminum seal with flip-off cap x 1 mL (Box of l’s)
RxVAT-exempt
Laboratorio Kemex S.A.
Delex Pharma International, Inc.
DR-XY47947
Apr 20, 2027
GemcilexGemcitabine(as hydrochloride)
200 mg Lyophilized Powder for Injection (IV)USP Type I colorless glass vials sealed with grey bromobutyl rubber stopper and aluminum seals with flip-off cap
RxVAT-exempt
Laboratorio Kemex S.A.
Delex Pharma International, Inc.
DR-XY47898
Apr 4, 2027
Gemcinat 1000Gemcitabine (as hydrochloride)
1 g Lyophilized Powder for IV Infusion50 mL-capacity USP Type I Tubular Glass Vial with gray bromobutyl rubber stopper and red aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Panacea Biotec Pharma LimitedIndia
Natco Lifesciences Philippines Inc.Importer: Medinova Pharmaceutical Inc.
DRP-13998-02
Jun 1, 2028
Gemcinat 200Gemcitabine (as hydrochloride)
200 mg Lyophilized Powder for IV Infusion10 mL- capacity USP Type I Tubular Glass Vial with gray bromobutyl rubber stopper and red aluminum flip-off seal (Box of 1's)
RxVAT-exempt
Panacea Biotec Pharma LimitedIndia
Natco Lifesciences Philippines Inc.Importer: Medinova Pharmaceutical Inc.
DRP-13999-01
Jun 1, 2028
Gemcisaph-1000Gemcitabine (As Hydrochloride)
1 g Lyophilized Powder for Injection (IV Infusion)50 mL USP Type-I Glass Vial
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.
DRP-13074
Nov 28, 2027
Gemcisaph-200Gemcitabine (As Hydrochloride)
200 mg Lyophilized Powder for Injection (IV Infusion)10 mL USP Type-I Glass Vial
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Nelpa Lifesciences, Inc.
DRP-13075
Nov 28, 2027
Gemcitrex-1000Gemcitabine (as hydrochloride)
1 g Lyophilized Powder for Injection for I.V. InfusionType I glass vial with grey bromobutyl stopper and aluminum flip-off lemon yellow colour seal (Box of 1's)
RxVAT-exempt
Shilpa Medicare LimitedIndia
Ambica International Corporation
DRP-9564
Mar 3, 2031
Gemcitrex-200Gemcitabine (as hydrochloride)
200 mg Lyophilized Powder for Injection for I.V. InfusionType I Glass Vial with Grey Bromobutyl Stopper and Aluminum Flip-Off Lemon Yellow Colour Seal (Box of 1's)
RxVAT-exempt
Shilpa Medicare LimitedIndia
Ambica International Corporation
DRP-9563
Feb 24, 2031
GemfonGemcitabine (as hydrochloride)
1g Lyophilized Powder for Injection (IV)In 50 ml Type I Clear, Colorless Glass vial with bromobutyl rubber stopper and blue aluminum flip-off seal Box of 1's
RxVAT-exempt
PT. FONKO INTERNATIONAL PHARMACEUTICALSIndonesia
Glorious Dexa Mandaya, Inc.
DRP-9338
Jan 16, 2030
GemfonGemcitabine (as hydrochloride)
200 mg Lyophilized Powder for InjectionIn 10ml Type I clear, colorless glass vial eith grey bromobutyl rubber stopper and blue aluminum flip-off seal (Box of 1's)
RxVAT-exempt
PT FONKO INTERNATIONAL PHARMACEUTICALSIndonesia
Glorious Dexa Mandaya, Inc.
DRP-9919
Jan 16, 2030
GemgetGemcitabine (as hydrochloride)
1 g Lyophilized Powder for Injection (IV)50 mL-capacity USP Type I clear glass vial with rubber stopper and aluminum green flip-off seal (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
2MG Incorporated
DRP-15465
Jul 11, 2029
Gemget 200Gemcitabine (as hydrochloride)
200 mg Lyophilized Powder for Injection (IV)10 mL-capacity, type I clear glass vial with rubber stopper and aluminum green flip-off seal (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
2MG Incorporated
DRP-16570
Apr 29, 2030
GemhexinGemcitabine (as hydrochloride)
1 g Lyophilized Powder for Injection (IV Infusion)Type I Clear Glass Vial with Bromobutyl Rubber Stopper and Blue Aluminum Flip-Off Seal Cap x l's (Box of l's)
RxVAT-exempt
SP Accure Labs Pvt. Ltd.India
Hexagon Pharmaceuticals
DR-XY47719
Feb 10, 2027
GemhopeGemcitabine (as hydrochloride)
1 g Lyophilized Powder for Injection (I.V. Infusion)53 mL colorless glass vial with elastomeric chlorobutyl stopper and aluminum seal with plastic green flip-off cap
RxVAT-exempt
Glenmark Generics S.A.Argentine Republic
Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals Limited
DRP-8100
Oct 19, 2031
GemhopeGemcitabine (as hydrochloride)
200 mg Lyophilized Powder for Injection (I.V. Infusion)9 mL colorless glass vial with elastomeric chlorobutyl stopper and aluminum seal with plastic green flip-off cap
RxVAT-exempt
Glenmark Generics S.A.Argentine Republic
Glenmark Philippines, Inc.Trader: Glenmark Pharmaceuticals Limited
DRP-8099
Sep 4, 2031
Gemibine-2000Gemcitabine
2g Lyophilized Powder for Injection (IV)USP Type I clear glass vial with gray butyl rubber stopper and aluminum flip-off seal x 100 mL (Box of l's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Accord Healthcare Limited-Philippine Branch Office
DR-XY47972
Apr 28, 2027
GemitaGemcitabine (as hydrochloride)
1 g Lyophilized Powder for Injection I.V. Infusion10 mL USP Type I Tubular, Clear Colorless Glass Vial with Fluoretec Lyotec Grey Rubber Stopper and Aluminum Flip-off over Seal in a box (Box of 1's)
RxVAT-exempt
Fresenius Kabi Oncology LimitedIndia
Fresenius Kabi Philippines, Inc.
DR-XY41774
Mar 11, 2031
GemitaGemcitabine (as hydrochloride)
200 mg Lyophilized Powder for Injection for I.V. Infusion10 mL USP Type I Tubular, Clear Colorless Glass Vial with Fluoretec Lyotec Grey Rubber Stopper and Aluminum Flip-Off Over Seal in a Box
RxVAT-exempt
Fresenius Kabi Oncology LimitedIndia
Fresenius Kabi Philippines, Inc.
DR-XY41773
Mar 11, 2031
GemlifeGemcitabine (as hydrochloride)
1 g Lyophilized Powder for Injection for I.V. InfusionUSP Type I clear moulded glass vial with grey bromobutyl rubber stopper and blue colored flip-off seal (Box of 1's)
RxVAT-exempt
ADMAC LifesciencesIndia
Pharmastar Int'l Trading Corp.
DRP-14643
Nov 14, 2028
Gemlife-200Gemcitabine (as hydrochloride)
200 mg Lyophilized Powder for Solution for I.V. Infusion10 mL-capacity USP Type I clear glass vial with slotted bromobutyl rubber plug and blue flip off seal (Box of 1 vial)
RxVAT-exempt
ADMAC LifesciencesIndia
Pharmastar Int'l Trading Corp.
DRP-14514
Sep 27, 2028
Gemosanz-1000Gemcitabine (as Hydrochloride)
1 g Powder for Solution for IV InfusionUSP Type I Clear Glass Vial with Slotted Rubber Plug and Blue Flip-off Seal x 50 mL (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Detoxicare Philippines, Inc.Importer: Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-8771
Nov 7, 2028
Gemosanz-200Gemcitabine (as Hydrochloride)
200 mg Powder for Solution for IV InfusionUSP Type I Clear Glass Vial with Slotted Rubber Plug and Blue Flip-Off Seal x 10 mL (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Detoxicare Philippines, Inc.Importer: Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-8770
Nov 7, 2028
GempowerGemcitabine Hydrochloride
1 g Powder for Injection50 mL USP Type I Flint Moulded Glass Vial (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Medethix, Inc.
DRP-10192
Sep 27, 2028
GemsafeGemcitabine (as hydrochloride)
1 g Lyophilized Powder for Injection (I.V.)Clear USP Type I Flint glass vial sealed with grey rubber closure, aluminum seal and sky blue flip-off cap x 50 mL (Box of 1's)
RxVAT-exempt
Getwell Pharma India Pvt. Ltd.India
Ambica International Corporation
DRP-6330
Sep 1, 2030
GemtabinGemcitabine (as Hydrochloride)
1 g Lyophilized Powder for IV InfusionClear, colorless Type I Glass Vial (Box of 1's)
RxVAT-exempt
Korea United Pharm. Inc.Republic of Korea
Qualimed Pharma Inc.
DR-XY34391
Nov 9, 2030
GemtabinGemcitabine (as Hydrochloride)
200 mg Lyophilized Powder for IV InfusionUSP Type I Clear Glass Vial with red flip-off seal (Box of 1's)
RxVAT-exempt
Korea United Pharm. Inc.Republic of Korea
Qualimed Pharma, Inc.
DR-XY35931
Apr 27, 2031
GemteroGemcitabine (as hydrochloride)
1g Powder for Solution for IV Infusion50mL Type I clear glass vial with gray bromobutyl rubber stopper and blue flip off seal (Box of 10's)
RxVAT-exempt
Hetero Labs Limited (Unit VI)India
Camber Pharmaceuticals, Inc.
DRP-7080
Jan 22, 2031
GemteroGemcitabine (as hydrochloride)
200 mg Lyophilized Powder for Injection (IV)USP Type I Vial x 10 mL with Blue Flip-off Seal in a box (Box of 12's)
RxVAT-exempt
Hetero Labs Limited (Unit VI)India
Camber Pharmaceuticals, Inc.
DRP-7587
Oct 14, 2031
Gemvex-1000Gemcitabine (as hydrochloride)
1 g Lyophilized Powder for Injection (I.V Infusion)50 mL Clear Glass Vial USP Type I (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd
DR-XY44613
Jun 5, 2030
Gemvex-200Gemcitabine (as hydrochloride)
200 mg Lyophilized Powder for Injection (I.V Infusion)10 mL USP Type 1 Tubular Flint Glass Vial (Box of 1’s)
RxVAT-exempt
Admac LifesciencesIndia
VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd
DR-XY44447
Apr 10, 2030
GemzarGemcitabine (as hydrochloride)
1 g Powder for Injection (I.V.)USP Type I Clear Glass Vial
RxVAT-exempt
Vianex S.A. - Plant CGreece
Zuellig Pharma Corporation
DR-XY42100
Feb 20, 2029
GemzarGemcitabine (as hydrochloride)
200 mg Lyophilized Powder for Injection (I.V.)USP Type I Clear and Colorless Glass Vial Box of 1's
RxVAT-exempt
Vianex S.A. - Plant CGreece
Zuellig Pharma Corporation
DR-XY40364
Feb 20, 2029
GemzibGemcitabine
200 mg Lyophilized Powder for Injection (I.V. Infusion)15 mL USP Type I glass vial, grey butyl rubber stopper, aluminum seal, and light-blue flip-off cap (Box of 1's)
RxVAT-exempt
Cisen Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-16010
Oct 17, 2029
GenbitacGemcitabine (as hydrochloride)
1 g Lyophilized Powder for Injection (I.V.)Clear USP Type I Flint glass vial sealed with grey rubber closure, aluminum seal and sky blue flip-off cap x 50 mL (Box of 1's)
RxVAT-exempt
Getwell Pharma India Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-6330-01
Sep 1, 2030
Gencivenz-1000Gemcitabine (as hydrochloride)
1 g Lyophilized Powder for Injection (I.V. Infusion)Type I flint flat bottom tubular glass vial with grey bromo butyl stopper and aluminum yellow flip off colour seal (Box of 1's)
RxVAT-exempt
Shilpa Medicare LimitedIndia
Ambica International Corporation
DRP-10644
Oct 26, 2031
Gencivenz-200Gemcitabine (as hydrochloride)
200 mg Lyophilized Powder for Injection (I.V. Infusion)Type I flint flat bottom tubular glass vial with grey bromo butyl stopper and aluminum yellow flip off colour seal (Box of 1's)
RxVAT-exempt
Shilpa Medicare LimitedIndia
Ambica International Corporation
DRP-10643
Oct 26, 2031
Getabin-100Gemcitabine
1 g Lyophilized Powder for Injection (IV)USP Type I Clear Glass Vial x 50 mL (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-6645
Apr 21, 2038
Getabin-1000Gemcitabine (as hydrochloride)
1g Lyophilized Powder for Intravenous InfusionUSP Type I Clear Moulded Glass Vial sealed with 20mm grey bromo butyl rubber stopper and 20mm blue flip-off seal x 50 mL (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-8894
May 29, 2030
Getabin-200Gemcitabine (as hydrochloride)
200 mg Lyophilized Powder for Intravenous InfusionUSP Type I Moulded Clear Glass Vial with 20 mm Bromobutyl Rubber Stopper and 20 mm Blue Flip-Off Seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-8892
May 29, 2030
Getanosan 200Gemcitabine (as hydrochloride)
200 mg Powder for Solution for Injection (IV)10 mL Type I Clear Glass Vial with Grey Rubber Vial Stopper and Aluminum Flip-off Seal (Box of 1's)
RxVAT-exempt
PT. Sanbe Farma (Unit 3)Indonesia
Macropharma Corporation
DRP-13807
Apr 26, 2028
InfusmartGemcitabine (as hydrochloride)
10 mg/mL Solution for Injection for I. V. Infusion (Ready-to-Infuse)Multilayer M312 infusion bag with M916M polyolefin tube and polycarbonate minitulipe M95A spike port with chlorobutyl (latex free) overwrapped in aluminum pouch x and 180 mL (Box of 1's)
RxVAT-exempt
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines, Inc.
DR-XY48436
Oct 27, 2027
LuocitabinGemcitabine Hydrochloride
200 mg Lyophilized Powder for IV Injection15 mL Type I Clear Glass Vial with Bromobutyl Rubber Stopper and Aluminum-Plastic Flip-off Seal (Box of 1's)
RxVAT-exempt
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.China
Luoxin Pharmaceuticals (PH) Corp.
DRP-15041
Mar 27, 2029
NoneGemcitabine Hydrochloride
1 g Powder for Injection50 mL USP Type I Flint Moulded Glass Vial (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
I.E. Medica, Inc.Importer: Medethix, Inc.
DRP-10192-01
Sep 27, 2028
NoneGemcitabine (as hydrochloride)
1 g Powder for Solution for Injection (I.V.)50 mL USP Type I clear glass vial stoppered with 20 mm double slotted bromo butyl rubber plug and sealed with 20 mm peach colored aluminium flip off seal (Box of 1's)
RxVAT-exempt
Adley Formulations Pvt. Ltd.India
Asa Life Philippines Limited Inc.
DRP-6013
Feb 24, 2031
NoneGemcitabine (as hydrochloride)
38 mg/mL (1 g/26.3 mL) Solution for Intravenous Infusion30 mL USP Type I Clear Glass Vial Box of 1's
RxVAT-exempt
Zydus Hospira Oncology Pvt. LimitedIndia
Importer: Pfizer, Inc.
DR-XY43942
Dec 5, 2029
NoneGemcitabine (as hydrochloride)
38 mg/mL (200 mg/5.3 mL) Solution for Intravenous Infusion10 mL USP Type I Clear Glass Vial Box of 1's
RxVAT-exempt
Zydus Hospira Oncology Private LimitedIndia
Importer: Pfizer, Inc.
DR-XY43941
Dec 5, 2029
Omnicure-1Gemcitabine (as hydrochloride)
1 g Lyophilized Powder for I.V. InfusionUSP Type I clear moulded glass vial with rubber bromo butyl plug and blue color flip off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Genace Pharma DistributorImporter: Suhitas Pharmaceuticals Inc.
DRP-12400-01
Aug 2, 2027
Omnicure-200Gemcitabine (as hydrochloride)
200 mg Lyophilized Powder for I.V. InfusionUSP Type I clear moulded glass vial with rubber bromo butyl plug and blue flip off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Genace Pharma DistributorImporter: Suhitas Pharmaceuticals Inc.
DRP-12401-1
Aug 2, 2027
Omnicure-200Gemcitabine (as hydrochloride)
200 mg Powder for Solution for Injection (I.V)10 mL USP Type I clear glass vial stoppered with 20 mm double slotted bromo butyl rubber plug and sealed with 20 mm peach colored aluminium flip-off seal (Box of 1's)
RxVAT-exempt
Adley Formulations Pvt. Ltd.India
Asa Life Philippines Limited Inc
DRP-6012
Feb 24, 2031
PyribeneGemcitabine Hydrochloride
1 g Powder for Injection50 mL USP Type I Flint Moulded Glass Vial (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. LtdIndia
I.E. Medica, Inc.Importer: Medethix, Inc.
DRP-10192-02
Sep 27, 2028
PyribeneGemcitabine (as hydrochloride)
200 mg Lyophilized Powder for Injection (IV)10 mL USP Type I Flint Tubular Glass Vial (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
I. E. Medica, Inc.Importer: Medethix, Inc.
DRP-10193-01
Sep 27, 2028
PyribineGemcitabine (as hydrochloride)
1 g Powder for Solution for I.V Infusion50 mL clear USP Type-I tubular vial sealed with grey colored bromo-butyl rubber stopper & red colored aluminium flip-off seal (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
Medethix, Inc.Importer: I.E Medica Inc.
DRP-6269-02
Mar 2, 2031
PyribineGemcitabine (as hydrochloride)
200 mg Powder for Solution for I.V infusion50mL clear USP Type-1 Tubular vial sealed with grey colored bromo-Butyl rubber stopper & red colored aluminium flip-off seal (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
Medethix Inc.Importer: I.E Medica Inc.
DRP-6270-01
Mar 6, 2031
SpagemGemcitabine (as hydrochloride)
1 g Lyophilized Powder for Injection for I.V. InfusionType I clear colourless glass vial with 20 mm gray bromobutyl rubber stopper and german blue coloured flip off aluminum seal (Box of 1's) al (Box of 1's)
RxVAT-exempt
SP Accure Labs Pvt. Ltd.India
Hexagon Pharmaceuticals
DRP-14625
Nov 7, 2028
SpagemGemcitabine (as hydrochloride)
200 mg Lyophilized Powder for Injection for I.V. InfusionType I clear colourless glass vial with 20 mm gray bromobutyl rubber stopper and german blue coloured flip off aluminum seal (Box of 1's)
RxVAT-exempt
SP Accure Labs Pvt. Ltd.India
Hexagon Pharmaceuticals
DRP-14626
Nov 7, 2028
ZefeiGemcitabine (as hydrochloride)
1 g Lyophilized Powder for Solution for Infusion (IV)USP Type I Borosilicate Clear Glass Vial with Bromobutyl Rubber Stopper and Aluminum Flip-off Seal x 50 mL (Box of 1's)
RxVAT-exempt
Jiangsu Hansoh Pharmaceutical Co., Ltd.China
Goodfellow Pharma Corporation
DR-XY33194
Jul 25, 2027
ZefeiGemcitabine (as hydrochloride)
200 mg Lyophilized Powder for Solution for Infusion (IV)USP Type I Borosilicate Clear Glass Vial with Bromobutyl Rubber Stopper and Aluminum Flip-off Seal x 10 mL (Box of 1's)
RxVAT-exempt
Jiangsu Hansoh Pharmaceutical Co., Ltd.China
Goodfellow Pharma Corporation
DR-XY33193
Jul 25, 2027
ZytogemGemcitabine (as hydrochloride)
1 g Lyophilized Powder for IV Infusion60 mL clear, colorless USP Type I glass vial with grey chlorobutyl rubber stopper and aluminum seal (Box of 1's)
RxVAT-exempt
Ildong Pharmaceutical Co., Ltd.Republic of Korea
International Apex Pharmaceutical, Inc.
DR-XY46385
Jun 25, 2030
ZytogemGemcitabine (as hydrochloride)
200 mg Lyophilized Powder for IV Infusion20 mL clear, colorless USP Type I glass vial with grey chlorobutyl rubber stopper and aluminum seal (Box of 1's)
RxVAT-exempt
Ildong Pharmaceutical Co., Ltd.Republic of Korea
International Apex Pharmaceutical, Inc.
DR-XY46384
Jun 25, 2030
(no brand name)Gemcitabine (As Hydrochloride)
1 g Lyophilized Powder for Injection (IV Infusion)50 mL USP Type I glass vial with grey butyl rubber stopper, aluminum seal and green PP flip-off cap (Box of 1's)
RxVAT-exempt
Venus Remedies, LimitedIndia
Ve Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd.
DRP-13119
Dec 2, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Gemcitabine for Injection, USP: 200 mg gemcitabine or 1 gram gemcitabine as a sterile white to off-white lyophilized powder in a single-dose vial for reconstitution. Gemcitabine for Injection: 200 mg or 1 gram lyophilized powder in single-dose vials for reconstitution. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Schedule-Dependent Toxicity: Increased toxicity with infusion time greater than 60 minutes or dosing more frequently than once weekly. (5.1)
  • Myelosuppression: Monitor for myelosuppression prior to each cycle and reduce or withhold dose for severe myelosuppression. (5.2, 5.8)
  • Severe Cutaneous Adverse Reactions (SCARs):Permanently discontinue gemcitabine injection if SCARs occur. (5.3)
  • Pulmonary Toxicity and Respiratory Failure: Discontinue Gemcitabine for Injection for unexplained dyspnea or other evidence of severe pulmonary toxicity. (5.4)
  • Hemolytic Uremic Syndrome (HUS): Monitor renal function prior to initiation and during treatment. Discontinue Gemcitabine for Injection for HUS or severe renal impairment. (5.5)
  • Hepatic Toxicity: Monitor hepatic function prior to initiation and during treatment. Discontinue Gemcitabine for Injection for severe hepatic toxicity. (5.6)
  • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females and males of reproductive potential to use effective contraception. (5.7, 8.1)
  • Exacerbation of Radiation Therapy Toxicity: May cause severe and life-threatening toxicity when administered during or within 7 days of radiation therapy. (5.8)
  • Capillary Leak Syndrome: Discontinue Gemcitabine for Injection. (5.9)
  • Posterior Reversible Encephalopathy Syndrome (PRES): Discontinue Gemcitabine for Injection. (5.10)
5.1 Schedule-Dependent Toxicity

5.1 Schedule-Dependent Toxicity In clinical trials evaluating the maximum tolerated dose of Gemcitabine for Injection, prolongation of the infusion time beyond 60 minutes or more frequent than weekly dosing resulted in an increased incidence of clinically significant hypotension, severe flu-like symptoms, myelosuppression, and asthenia. The half-life of Gemcitabine for Injection is influenced by the length of the infusion [see Clinical Pharmacology (12.3)].

Refer to the recommended Gemcitabine for Injection dosage [see Dosage and Administration (2.1, 2.2, 2.3, 2.4)].

5.2 Myelosuppression

5.2 Myelosuppression Myelosuppression manifested by neutropenia, thrombocytopenia, and anemia occurs with Gemcitabine for Injection as a single agent and the risks are increased when Gemcitabine for Injection is combined with other cytotoxic drugs. In clinical trials, Grade 3 or 4 neutropenia, anemia, and thrombocytopenia occurred in 25%, 8%, and 5%, respectively of the 979 patients who received single agent Gemcitabine for Injection.

The frequencies of Grade 3 or 4 neutropenia, anemia, and thrombocytopenia varied from 48% to 71%, 8% to 28%, and 5% to 55%, respectively, in patients receiving Gemcitabine for Injection in combination with another drug [see Adverse Reactions (6.1)]. Prior to each dose of Gemcitabine for Injection, obtain a complete blood count (CBC) with a differential and a platelet count.

Modify the dosage as recommended [see Dosage and Administration (2.1, 2.2, 2.3, 2.4)].

5.3 Severe Cutaneous Adverse Reactions (SCARS)

5.3 Severe Cutaneous Adverse Reactions (SCARS) SCARs, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), which can be life-threatening or fatal, have been reported in association with gemcitabine treatment [see Adverse Reactions (6.2)]. Monitor patients for signs and symptoms of severe cutaneous adverse reactions.

Permanently discontinue gemcitabine in patients who develop SCARs.

5.4 Pulmonary Toxicity and Respiratory Failure

5.4 Pulmonary Toxicity and Respiratory Failure Pulmonary toxicity, including interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, and adult respiratory distress syndrome (ARDS), has been reported. In some cases, these pulmonary events can lead to fatal respiratory failure despite the discontinuation of therapy.

The onset of pulmonary symptoms may occur up to 2 weeks after the last dose of Gemcitabine for Injection [see Adverse Reactions (6.1, 6.2)]. Permanently discontinue Gemcitabine for Injection in patients who develop unexplained dyspnea, with or without bronchospasm, or evidence of severe pulmonary toxicity.

5.5 Hemolytic Uremic Syndrome

5.5 Hemolytic Uremic Syndrome Hemolytic uremic syndrome (HUS), including fatalities from renal failure or the requirement for dialysis, can occur with Gemcitabine for Injection. In clinical trials, HUS occurred in 0.25% of 2429 patients. Most fatal cases of renal failure were due to HUS [see Adverse Reactions (6.1)]. Serious cases of thrombotic microangiopathy other than HUS have been reported with Gemcitabine for Injection [see Adverse Reactions (6.2)].

Assess renal function prior to initiation of Gemcitabine for Injection and periodically during treatment. Consider the diagnosis of HUS in patients who develop anemia with evidence of microangiopathic hemolysis; increased bilirubin or LDH; reticulocytosis; severe thrombocytopenia; or renal failure (increased serum creatinine or BUN).

Permanently discontinue Gemcitabine for Injection in patients with HUS or severe renal impairment. Renal failure may not be reversible even with the discontinuation of therapy.

5.6 Hepatic Toxicity

5.6 Hepatic Toxicity Drug-induced liver injury, including liver failure and death, has been reported in patients receiving Gemcitabine for Injection alone or with other potentially hepatotoxic drugs [see Adverse Reactions (6.1, 6.2)]. Administration of Gemcitabine for Injection in patients with concurrent liver metastases or a pre-existing medical history of hepatitis, alcoholism, or liver cirrhosis can lead to exacerbation of the underlying hepatic insufficiency.

Assess hepatic function prior to initiation of Gemcitabine for Injection and periodically during treatment. Permanently discontinue Gemcitabine for Injection in patients who develop severe hepatic toxicity.

5.7 Embryo-Fetal Toxicity

5.7 Embryo-Fetal Toxicity Based on animal data and its mechanism of action, Gemcitabine for Injection can cause fetal harm when administered to a pregnant woman. Gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Gemcitabine for Injection and for 6 months after the final dose.

Advise male patients with female partners of reproductive potential to use effective contraception during treatment with Gemcitabine for Injection and for 3 months following the final dose [see Use in Specific Populations (8.1, 8.3)].

5.8 Exacerbation of Radiation Therapy Toxicity

5.8 Exacerbation of Radiation Therapy Toxicity Gemcitabine for Injection is not recommended for use in combination with radiation therapy. Concurrent (given together or ≤7 days apart) Life-threatening mucositis, especially esophagitis and pneumonitis occurred in a trial in which Gemcitabine for Injection was administered at a dose of 1000 mg/m 2 to patients with non-small cell lung cancer for up to 6 consecutive weeks concurrently with thoracic radiation.

Non-concurrent (given >7 days apart) Excessive toxicity has not been observed when Gemcitabine for Injection is administered more than 7 days before or after radiation. Radiation recall has been reported in patients who received Gemcitabine for Injection after prior radiation.

5.9 Capillary Leak Syndrome

5.9 Capillary Leak Syndrome Capillary leak syndrome (CLS) with severe consequences has been reported in patients receiving Gemcitabine for Injection as a single agent or in combination with other chemotherapeutic agents [see Adverse Reactions (6.2)]. Permanently discontinue Gemcitabine for Injection if CLS develops during therapy.

5.10 Posterior Reversible Encephalopathy Syndrome

5.10 Posterior Reversible Encephalopathy Syndrome Posterior reversible encephalopathy syndrome (PRES) has been reported in patients receiving Gemcitabine for Injection as a single agent or in combination with other chemotherapeutic agents [see Adverse Reactions (6.2)]. PRES can present with headache, seizure, lethargy, hypertension, confusion, blindness, and other visual and neurologic disturbances.

Confirm the diagnosis of PRES with magnetic resonance imaging (MRI). Permanently discontinue Gemcitabine for Injection if PRES develops during therapy.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity [see Contraindications (4)] Schedule-Dependent Toxicity [see Warnings and Precautions (5.1)] Myelosuppression [see Warnings and Precautions (5.2)] Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.3)] Pulmonary Toxicity and Respiratory Failure [see Warnings and Precautions (5.4)] Hemolytic Uremic Syndrome [see Warnings and Precautions (5.5)] Hepatic Toxicity [see Warnings and Precautions (5.6)] Exacerbation of Radiation Therapy Toxicity [see Warnings and Precautions (5.8)] Capillary Leak Syndrome [see Warnings and Precautions (5.9)] Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions (5.10)] The most common adverse reactions for the single agent (≥20%) are nausea/vomiting, anemia, increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), neutropenia, increased alkaline phosphatase, proteinuria, fever, hematuria, rash, thrombocytopenia, dyspnea, and edema. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Single Agent The data described below reflect exposure to Gemcitabine for Injection as a single agent administered at doses between 800 mg/m 2 to 1250 mg/m 2 intravenously over 30 minutes once weekly in 979 patients with various malignancies.

The most common (≥20%) adverse reactions of single agent Gemcitabine for Injection are nausea/vomiting, anemia, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), neutropenia, increased alkaline phosphatase, proteinuria, fever, hematuria, rash, thrombocytopenia, dyspnea, and edema. The most common (≥5%) Grade 3 or 4 adverse reactions were neutropenia, nausea/vomiting, increased ALT, increased alkaline phosphatase, anemia, increased AST, and thrombocytopenia.

Approximately 10% of the 979 patients discontinued Gemcitabine for Injection due to adverse reactions. Adverse reactions resulting in discontinuation of Gemcitabine for Injection in 2% of 979 patients were cardiovascular adverse reactions (myocardial infarction, cerebrovascular accident, arrhythmia, and hypertension) and adverse reactions resulting in discontinuation of Gemcitabine for Injection in <1% of 979 patients were anemia, thrombocytopenia, hepatic dysfunction, renal dysfunction, nausea/vomiting, fever, rash, dyspnea, hemorrhage, infection, stomatitis, somnolence, flu-like syndrome, and edema.

Tables 5 and 6 present the incidence of selected adverse reactions and laboratory abnormalities reported in patients with various malignancies receiving single agent Gemcitabine for Injection across 5 clinical trials. Additional clinically significant adverse reactions are provided following Table 6. Table 5: Selected Adverse Reactions Occurring in ≥10% of Patients Receiving Single Agent Gemcitabine for Injection a a Grade based on criteria from the World Health Organization (WHO). b For approximately 60% of patients, non-laboratory adverse reactions were graded only if assessed to be possibly drug-related. c N=699 to 974; all patients with laboratory or non-laboratory data.

Adverse Reactions b Gemcitabine for Injection c All Grades (%) Grade 3 (%) Grade 4 (%) Nausea and Vomiting 69 13 1 Fever 41 2 0 Rash 30 <1 0 Dyspnea 23 3 <1 Diarrhea 19 1 0 Hemorrhage 17 <1 <1 Infection 16 1 <1 Alopecia 15 <1 0 Stomatitis 11 <1 0 Somnolence 11 <1 <1 Paresthesias 10 <1 0 Table 6: Selected Laboratory Abnormalities Occurring in Patients Receiving Single Agent Gemcitabine for Injection a a Grade based on criteria from the WHO. b Regardless of causality. c N=699 to 974; all patients with laboratory or non-laboratory data. Laboratory Abnormality b Gemcitabine for Injection c All Grades (%) Grade 3 (%) Grade 4 (%) Hematologic Anemia 68 7 1 Neutropenia 63 19 6 Thrombocytopenia 24 4 1 Hepatic Increased ALT 68 8 2 Increased AST 67 6 2 Increased Alkaline Phosphatase 55 7 2 Hyperbilirubinemia 13 2 <1 Renal Proteinuria 45 <1 0 Hematuria 35 <1 0 Increased BUN 16 0 0 Increased Creatinine 8 <1 0 Additional adverse reactions include the following: Transfusion requirements: Red blood cell transfusions (19%); platelet transfusions (<1%) Edema: Edema (13%), peripheral edema (20%), generalized edema (<1%) Flu-like symptoms: Fever, asthenia, anorexia, headache, cough, chills, myalgia, asthenia insomnia, rhinitis, sweating and/or malaise (19%) Infection: Sepsis (<1%) Extravasation: Injection-site reactions (4%) Allergic: Bronchospasm (<2%); anaphylactoid reactions Ovarian Cancer Tables 7 and 8 present the incidence of selected adverse reactions and laboratory abnormalities, occurring in ≥10% of gemcitabine for injection-treated patients and at a higher incidence in the Gemcitabine for Injection with carboplatin arm, reported in a randomized trial (Study 1) of Gemcitabine for Injection with carboplatin (n=175) compared to carboplatin alone (n=174) for the second-line treatment of ovarian cancer in women with disease that had relapsed more than 6 months following first-line platinum-based chemotherapy [see Clinical Studies (14.1)].

Additional clinically significant adverse reactions, occurring in <10% of patients, are provided following Table 8. The proportion of patients with dose adjustments for carboplatin (1.8% versus 3.8%), doses of carboplatin omitted (0.2% versus 0) and discontinuing treatment for adverse reactions (11% versus 10%), were similar between arms.

Dose adjustment for Gemcitabine for Injection occurred in 10% of patients and Gemcitabine for Injection dose was omitted in 14% of patients in the Gemcitabine for Injection/carboplatin arm. Table 7: Adverse Reactions Occurring in >10% of Patients Receiving Gemcitabine with Carboplatin and at Higher Incidence than in Patients Receiving Single Agent Carboplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 1 a a Grade based on National Cancer Institute CTC Version 2.0. b Regardless of causality.

Adverse Reactions b Gemcitabine for Injection/Carboplatin Carboplatin (N=175) (N=174) All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%) Nausea 69 6 0 61 3 0 Alopecia 49 0 0 17 0 0 Vomiting 46 6 0 36 2 <1 Constipation 42 6 1 37 3 0 Fatigue 40 3 <1 32 5 0 Diarrhea 25 3 0 14 <1 0 Stomatitis/Pharyngitis 22 <1 0 13 0 0 Table 8: Laboratory Abnormalities Occurring in Patients Receiving Gemcitabine with Carboplatin and at Higher Incidence than in Patients Receiving Single Agent Carboplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 1 a a Grade based on National Cancer Institute CTC Version 2.0. b Regardless of causality. c Percent of patients receiving transfusions. Transfusions are not CTC-graded events.

Blood transfusions included both packed red blood cells and whole blood. Laboratory Abnormality b Gemcitabine for Injection/Carboplatin Carboplatin (N=175) (N=174) All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%) Hematologic Neutropenia 90 42 29 58 11 1 Anemia 86 22 6 75 9 2 Thrombocytopenia 78 30 5 57 10 1 RBC Transfusions c 38 - - 15 - - Platelet Transfusions c 9 - - 3 - - Hematopoietic growth factors were administered more frequently in the Gemcitabine for Injection-containing arm: leukocyte growth factor (24% and 10%) and erythropoiesis-stimulating agent (7% and 3.9%).

The following clinically relevant Grade 3 and 4 adverse reactions occurred more frequently in the Gemcitabine for Injection with carboplatin arm: dyspnea (3.4% versus 2.9%), febrile neutropenia (1.1% versus 0), hemorrhagic event (2.3% versus 1.1%), motor neuropathy (1.1% versus 0.6%), and rash/desquamation (0.6% versus 0). Breast Cancer Tables 9 and 10 present the incidence of selected adverse reactions and laboratory abnormalities, occurring in ≥10% of Gemcitabine for Injection-treated patients and at a higher incidence in the Gemcitabine for Injection with paclitaxel arm, reported in a randomized trial (Study 2) of Gemcitabine for Injection with paclitaxel (n=262) compared to paclitaxel alone (n=259) for the first-line treatment of metastatic breast cancer (MBC) in women who received anthracycline-containing chemotherapy in the adjuvant/neo-adjuvant setting or for whom anthracyclines were contraindicated [see Clinical Studies (14.2)].

Additional clinically significant adverse reactions, occurring in <10% of patients, are provided following Table 10. The requirement for dose reduction of paclitaxel were higher for patients in the Gemcitabine for Injection/paclitaxel arm (5% versus 2%). The number of paclitaxel doses omitted (<1%), the proportion of patients discontinuing treatment for adverse reactions (7% versus 5%) and the number of treatment-related deaths (1 patient in each arm) were similar between the two arms.

Table 9: Selected Adverse Reactions Occurring in Patients Receiving Gemcitabine with Paclitaxel and at Higher Incidence than in Patients Receiving Single Agent Paclitaxel [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 2 a a Grade based on National Cancer Institute CTC Version 2.0. b Non-laboratory events were graded only if assessed to be possibly drug-related. Adverse Reactions b Gemcitabine for Injection/Paclitaxel Paclitaxel (N=262) (N=259) All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%) Alopecia 90 14 4 92 19 3 Neuropathy-Sensory 64 5 <1 58 3 0 Nausea 50 1 0 31 2 0 Fatigue 40 6 <1 28 1 <1 Vomiting 29 2 0 15 2 0 Diarrhea 20 3 0 13 2 0 Anorexia 17 0 0 12 <1 0 Neuropathy-Motor 15 2 <1 10 <1 0 Stomatitis/Pharyngitis 13 1 <1 8 <1 0 Fever 13 <1 0 3 0 0 Rash/Desquamation 11 <1 <1 5 0 0 Febrile Neutropenia 6 5 <1 2 1 0 Table 10: Selected Laboratory Abnormalities Occurring in >10% of Patients Receiving Gemcitabine with Paclitaxel and at a Higher Incidence than Patients Receiving Single Agent Paclitaxel [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 2 a a Grade based on National Cancer Institute CTC Version 2.0. b Regardless of causality.

Laboratory Abnormality b Gemcitabine for Injection/Paclitaxel Paclitaxel (N=262) (N=259) All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%) Hematologic Anemia 69 6 1 51 3 <1 Neutropenia 69 31 17 31 4 7 Thrombocytopenia 26 5 <1 7 <1 <1 Hepatobiliary Increased ALT 18 5 <1 6 <1 0 Increased AST 16 2 0 5 <1 0 Clinically relevant Grade 3 or 4 dyspnea occurred with a higher incidence in the Gemcitabine for Injection with paclitaxel arm compared with the paclitaxel arm (1.9% versus 0). Non-Small Cell Lung Cancer Tables 11 and 12 present the incidence of selected adverse reactions and laboratory abnormalities occurring in ≥10% of Gemcitabine for Injection-treated patients and at a higher incidence in the Gemcitabine for Injection with cisplatin arm, reported in a randomized trial (Study 3) of Gemcitabine for Injection with cisplatin (n=260) administered in 28-day cycles as compared to cisplatin alone (n=262) in patients receiving first-line treatment for locally advanced or metastatic NSCLC [see Clinical Studies (14.3)].

Patients randomized to Gemcitabine for Injection with cisplatin received a median of 4 cycles of treatment and those randomized to cisplatin alone received a median of 2 cycles of treatment. In this trial, the requirement for dose adjustments (>90% versus 16%), discontinuation of treatment for adverse reactions (15% versus 8%), and the proportion of patients hospitalized (36% versus 23%) were all higher for patients receiving Gemcitabine for Injection with cisplatin compared to those receiving cisplatin alone.

The incidence of febrile neutropenia (3% versus <1%), sepsis (4% versus 1%), Grade 3 cardiac dysrhythmias (3% versus <1%) were all higher in the Gemcitabine for Injection with cisplatin arm compared to the cisplatin alone arm. The two-drug combination was more myelosuppressive with 4 (1.5%) possibly treatment-related deaths, including 3 resulting from myelosuppression with infection and one case of renal failure associated with pancytopenia and infection.

No deaths due to treatment were reported on the cisplatin arm. Table 11: Selected Adverse Reactions Occurring in ≥10% of Patients Receiving Gemcitabine with Cisplatin and at Higher Incidence than in Patients Receiving Single Agent Cisplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 3 a a Grade based on National Cancer Institute Common Toxicity Criteria (CTC). b Non-laboratory events were graded only if assessed to be possibly drug-related. c N=217 to 253; all Gemcitabine for Injection/cisplatin patients with laboratory or non-laboratory data. d N=213 to 248; all cisplatin patients with laboratory or non-laboratory data.

Adverse Reactions b Gemcitabine for Injection/Cisplatin c Cisplatin d All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%) Nausea 93 25 2 87 20 <1 Vomiting 78 11 12 71 10 9 Alopecia 53 1 0 33 0 0 Neuro Motor 35 12 0 15 3 0 Diarrhea 24 2 2 13 0 0 Neuro Sensory 23 1 0 18 1 0 Infection 18 3 2 12 1 0 Fever 16 0 0 5 0 0 Neuro Cortical 16 3 1 9 1 0 Neuro Mood 16 1 0 10 1 0 Local 15 0 0 6 0 0 Neuro Headache 14 0 0 7 0 0 Stomatitis 14 1 0 5 0 0 Hemorrhage 14 1 0 4 0 0 Hypotension 12 1 0 7 1 0 Rash 11 0 0 3 0 0 Table 12: Selected Laboratory Abnormalities Occurring in >10% of Patients Receiving Gemcitabine with Cisplatin and at Higher Incidence than in Patients Receiving Single Agent Cisplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 3 a a Grade based on National Cancer Institute CTC. b Regardless of causality. c N=217 to 253; all Gemcitabine for Injection/cisplatin patients with laboratory or non-laboratory data. d N=213 to 248; all cisplatin patients with laboratory or non-laboratory data. e Percent of patients receiving transfusions. Percent transfusions are not CTC-graded events.

Laboratory Abnormality b Gemcitabine for Injection/Cisplatin c Cisplatin d All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%) Hematologic Anemia 89 22 3 67 6 1 Thrombocytopenia 85 25 25 13 3 1 Neutropenia 79 22 35 20 3 1 Lymphopenia 75 25 18 51 12 5 RBC Transfusions e 39 - - 13 - - Platelet Transfusions e 21 - - <1 - - Hepatic Increased Transaminases 22 2 1 10 1 0 Increased Alkaline Phosphatase 19 1 0 13 0 0 Renal Increased Creatinine 38 4 <1 31 2 <1 Proteinuria 23 0 0 18 0 0 Hematuria 15 0 0 13 0 0 Other Laboratory Hyperglycemia 30 4 0 23 3 0 Hypomagnesemia 30 4 3 17 2 0 Hypocalcemia 18 2 0 7 0 <1 Tables 13 and 14 present the incidence of selected adverse reactions and laboratory abnormalities occurring in ≥10% of Gemcitabine for Injection-treated patients and at a higher incidence in the Gemcitabine for Injection with cisplatin arm, reported in a randomized trial (Study 4) of Gemcitabine for Injection with cisplatin (n=69) administered in 21-day cycles as compared to etoposide with cisplatin (n=66) in patients receiving first-line treatment for locally advanced or metastatic NSCLC [see Clinical Studies (14.3)]. Additional clinically significant adverse reactions are provided following Table 14.

Patients in the Gemcitabine for Injection/cisplatin (GC) arm received a median of 5 cycles and those in the etoposide/cisplatin (EC) arm received a median of 4 cycles. The majority of patients receiving more than one cycle of treatment required dose adjustments; 81% in the GC arm and 68% in the EC arm. The incidence of hospitalizations for adverse reactions was 22% in the GC arm and 27% in the EC arm.

The proportion of patients who discontinued treatment for adverse reactions was higher in the GC arm (14% versus 8%). The proportion of patients who were hospitalized for febrile neutropenia was lower in the GC arm (7% versus 12%). There was one death attributed to treatment, a patient with febrile neutropenia and renal failure, which occurred in the GC arm.

Table 13: Selected Adverse Reactions in Patients Receiving Gemcitabine with Cisplatin in Study 4 a a Grade based on criteria from the WHO. b Non-laboratory events were graded only if assessed to be possibly drug-related. Pain data were not collected. c N=67 to 69; all Gemcitabine for Injection/cisplatin patients with laboratory or non-laboratory data. d N=57 to 63; all Etoposide/cisplatin patients with laboratory or non-laboratory data. e Flu-like syndrome and edema were not graded.

Adverse Reactions b Gemcitabine for Injection/Cisplatin c Etoposide/Cisplatin d All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%) Nausea and Vomiting 96 35 4 86 19 7 Alopecia 77 13 0 92 51 0 Paresthesias 38 0 0 16 2 0 Infection 28 3 1 21 8 0 Stomatitis 20 4 0 18 2 0 Diarrhea 14 1 1 13 0 2 Edema e 12 - - 2 - - Rash 10 0 0 3 0 0 Hemorrhage 9 0 3 3 0 3 Fever 6 0 0 3 0 0 Somnolence 3 0 0 3 2 0 Flu-like Syndrome e 3 - - 0 - - Dyspnea 1 0 1 3 0 0 Table 14: Selected Laboratory Abnormalities Occurring in Patients Receiving Gemcitabine with Cisplatin in Study 4 a a Grade based on criteria from the WHO. b Regardless of causality. c N=67 to 69; all Gemcitabine for Injection/cisplatin patients with laboratory or non-laboratory data. d N=57 to 63; all Etoposide/cisplatin patients with laboratory or non-laboratory data. e WHO grading scale not applicable to proportion of patients with transfusions. Laboratory Abnormality b Gemcitabine for Injection/Cisplatin c Etoposide/Cisplatin d All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%) Hematologic Anemia 88 22 0 77 13 2 Neutropenia 88 36 28 87 20 56 Thrombocytopenia 81 39 16 45 8 5 RBC Transfusions c 29 - - 21 - - Platelet Transfusions e 3 - - 8 - - Hepatic Increased Alkaline Phosphatase 16 0 0 11 0 0 Increased ALT 6 0 0 12 0 0 Increased AST 3 0 0 11 0 0 Renal Hematuria 22 0 0 10 0 0 Proteinuria 12 0 0 5 0 0 Increased BUN 6 0 0 4 0 0 Increased Creatinine 2 0 0 2 0 0

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of Gemcitabine for Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and lymphatic system: Thrombotic microangiopathy (TMA) Cardiovascular: Congestive heart failure, myocardial infarction, arrhythmias, supraventricular arrhythmias Vascular: Peripheral vasculitis, gangrene, capillary leak syndrome Skin: Cellulitis, pseudocellulitis, severe cutaneous adverse reactions (SCARS), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalize exanthematous pustulosis (AGEP); desquamation and bullous skin eruptions Hepatic: Hepatic failure, hepatic veno-occlusive disease Pulmonary: Interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, adult respiratory distress syndrome (ARDS), pulmonary eosinophilia Nervous System: Posterior reversible encephalopathy syndrome (PRES)

Adverse reaction frequency tables (US label) US FDA label
Table 5: Selected Adverse Reactions Occurring in ≥10% of Patients Receiving Single Agent Gemcitabine for Injectiona
a Grade based on criteria from the World Health Organization (WHO).
b For approximately 60% of patients, non-laboratory adverse reactions were graded only if assessed to be possibly drug-related.
c N=699 to 974; all patients with laboratory or non-laboratory data.
Adverse Reactions b Gemcitabine for Injection c
All Grades (%) Grade 3 (%) Grade 4 (%)
Nausea and Vomiting 69 13 1
Fever 41 2 0
Rash 30 <1 0
Dyspnea 23 3 <1
Diarrhea 19 1 0
Hemorrhage 17 <1 <1
Infection 16 1 <1
Alopecia 15 <1 0
Stomatitis 11 <1 0
Somnolence 11 <1 <1
Paresthesias 10 <1 0
Table 6: Selected Laboratory Abnormalities Occurring in Patients Receiving Single Agent Gemcitabine for Injectiona
a Grade based on criteria from the WHO.
b Regardless of causality.
c N=699 to 974; all patients with laboratory or non-laboratory data.
Laboratory Abnormality b Gemcitabine for Injection c
All Grades (%) Grade 3 (%) Grade 4 (%)
Hematologic
Anemia 68 7 1
Neutropenia 63 19 6
Thrombocytopenia 24 4 1
Hepatic
Increased ALT 68 8 2
Increased AST 67 6 2
Increased Alkaline Phosphatase 55 7 2
Hyperbilirubinemia 13 2 <1
Renal
Proteinuria 45 <1 0
Hematuria 35 <1 0
Increased BUN 16 0 0
Increased Creatinine 8 <1 0
Table 7: Adverse Reactions Occurring in >10% of Patients Receiving Gemcitabine with Carboplatin and at Higher Incidence than in Patients Receiving Single Agent Carboplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 1a
a Grade based on National Cancer Institute CTC Version 2.0.
b Regardless of causality.
Adverse Reactions b Gemcitabine for Injection/Carboplatin Carboplatin
(N=175) (N=174)
All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%)
Nausea 69 6 0 61 3 0
Alopecia 49 0 0 17 0 0
Vomiting 46 6 0 36 2 <1
Constipation 42 6 1 37 3 0
Fatigue 40 3 <1 32 5 0
Diarrhea 25 3 0 14 <1 0
Stomatitis/Pharyngitis 22 <1 0 13 0 0
Table 8: Laboratory Abnormalities Occurring in Patients Receiving Gemcitabine with Carboplatin and at Higher Incidence than in Patients Receiving Single Agent Carboplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 1a
a Grade based on National Cancer Institute CTC Version 2.0.
b Regardless of causality.
c Percent of patients receiving transfusions. Transfusions are not CTC-graded events. Blood transfusions included both packed red blood cells and whole blood.
Laboratory Abnormality b Gemcitabine for Injection/Carboplatin Carboplatin
(N=175) (N=174)
All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%)
Hematologic
Neutropenia 90 42 29 58 11 1
Anemia 86 22 6 75 9 2
Thrombocytopenia 78 30 5 57 10 1
RBC Transfusionsc 38 - - 15 - -
Platelet Transfusionsc 9 - - 3 - -
Table 9: Selected Adverse Reactions Occurring in Patients Receiving Gemcitabine with Paclitaxel and at Higher Incidence than in Patients Receiving Single Agent Paclitaxel [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 2a
a Grade based on National Cancer Institute CTC Version 2.0.
b Non-laboratory events were graded only if assessed to be possibly drug-related.
Adverse Reactions b Gemcitabine for Injection/Paclitaxel Paclitaxel
(N=262) (N=259)
All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%)
Alopecia 90 14 4 92 19 3
Neuropathy-Sensory 64 5 <1 58 3 0
Nausea 50 1 0 31 2 0
Fatigue 40 6 <1 28 1 <1
Vomiting 29 2 0 15 2 0
Diarrhea 20 3 0 13 2 0
Anorexia 17 0 0 12 <1 0
Neuropathy-Motor 15 2 <1 10 <1 0
Stomatitis/Pharyngitis 13 1 <1 8 <1 0
Fever 13 <1 0 3 0 0
Rash/Desquamation 11 <1 <1 5 0 0
Febrile Neutropenia 6 5 <1 2 1 0
Table 10: Selected Laboratory Abnormalities Occurring in >10% of Patients Receiving Gemcitabine with Paclitaxel and at a Higher Incidence than Patients Receiving Single Agent Paclitaxel [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 2a
a Grade based on National Cancer Institute CTC Version 2.0.
b Regardless of causality.
Laboratory Abnormality b Gemcitabine for Injection/Paclitaxel Paclitaxel
(N=262) (N=259)
All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%)
Hematologic
Anemia 69 6 1 51 3 <1
Neutropenia 69 31 17 31 4 7
Thrombocytopenia 26 5 <1 7 <1 <1
Hepatobiliary
Increased ALT 18 5 <1 6 <1 0
Increased AST 16 2 0 5 <1 0
Table 11: Selected Adverse Reactions Occurring in ≥10% of Patients Receiving Gemcitabine with Cisplatin and at Higher Incidence than in Patients Receiving Single Agent Cisplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 3a
a Grade based on National Cancer Institute Common Toxicity Criteria (CTC).
b Non-laboratory events were graded only if assessed to be possibly drug-related.
c N=217 to 253; all Gemcitabine for Injection/cisplatin patients with laboratory or non-laboratory data.
d N=213 to 248; all cisplatin patients with laboratory or non-laboratory data.
Adverse Reactions b Gemcitabine for Injection/Cisplatin c Cisplatin d
All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%)
Nausea 93 25 2 87 20 <1
Vomiting 78 11 12 71 10 9
Alopecia 53 1 0 33 0 0
Neuro Motor 35 12 0 15 3 0
Diarrhea 24 2 2 13 0 0
Neuro Sensory 23 1 0 18 1 0
Infection 18 3 2 12 1 0
Fever 16 0 0 5 0 0
Neuro Cortical 16 3 1 9 1 0
Neuro Mood 16 1 0 10 1 0
Local 15 0 0 6 0 0
Neuro Headache 14 0 0 7 0 0
Stomatitis 14 1 0 5 0 0
Hemorrhage 14 1 0 4 0 0
Hypotension 12 1 0 7 1 0
Rash 11 0 0 3 0 0
Table 12: Selected Laboratory Abnormalities Occurring in >10% of Patients Receiving Gemcitabine with Cisplatin and at Higher Incidence than in Patients Receiving Single Agent Cisplatin [Between Arm Difference of ≥5% (All Grades) or ≥2% (Grades 3-4)] in Study 3a
a Grade based on National Cancer Institute CTC.
b Regardless of causality.
c N=217 to 253; all Gemcitabine for Injection/cisplatin patients with laboratory or non-laboratory data.
d N=213 to 248; all cisplatin patients with laboratory or non-laboratory data.
e Percent of patients receiving transfusions. Percent transfusions are not CTC-graded events.
Laboratory Abnormality b Gemcitabine for Injection/Cisplatin c Cisplatin d
All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%)
Hematologic
Anemia 89 22 3 67 6 1
Thrombocytopenia 85 25 25 13 3 1
Neutropenia 79 22 35 20 3 1
Lymphopenia 75 25 18 51 12 5
RBC Transfusionse 39 - - 13 - -
Platelet Transfusionse 21 - - <1 - -
Hepatic
Increased Transaminases 22 2 1 10 1 0
Increased Alkaline Phosphatase 19 1 0 13 0 0
Renal
Increased Creatinine 38 4 <1 31 2 <1
Proteinuria 23 0 0 18 0 0
Hematuria 15 0 0 13 0 0
Other Laboratory
Hyperglycemia 30 4 0 23 3 0
Hypomagnesemia 30 4 3 17 2 0
Hypocalcemia 18 2 0 7 0 <1
Table 13: Selected Adverse Reactions in Patients Receiving Gemcitabine with Cisplatin in Study 4a
a Grade based on criteria from the WHO.
b Non-laboratory events were graded only if assessed to be possibly drug-related. Pain data were not collected.
c N=67 to 69; all Gemcitabine for Injection/cisplatin patients with laboratory or non-laboratory data.
d N=57 to 63; all Etoposide/cisplatin patients with laboratory or non-laboratory data.
e Flu-like syndrome and edema were not graded.
Adverse Reactions b Gemcitabine for Injection/Cisplatin c Etoposide/Cisplatin d
All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%)
Nausea and Vomiting 96 35 4 86 19 7
Alopecia 77 13 0 92 51 0
Paresthesias 38 0 0 16 2 0
Infection 28 3 1 21 8 0
Stomatitis 20 4 0 18 2 0
Diarrhea 14 1 1 13 0 2
Edemae 12 - - 2 - -
Rash 10 0 0 3 0 0
Hemorrhage 9 0 3 3 0 3
Fever 6 0 0 3 0 0
Somnolence 3 0 0 3 2 0
Flu-like Syndromee 3 - - 0 - -
Dyspnea 1 0 1 3 0 0
Table 14: Selected Laboratory Abnormalities Occurring in Patients Receiving Gemcitabine with Cisplatin in Study 4a
a Grade based on criteria from the WHO.
b Regardless of causality.
c N=67 to 69; all Gemcitabine for Injection/cisplatin patients with laboratory or non-laboratory data.
d N=57 to 63; all Etoposide/cisplatin patients with laboratory or non-laboratory data.
e WHO grading scale not applicable to proportion of patients with transfusions.
Laboratory Abnormality b Gemcitabine for Injection/Cisplatin c Etoposide/Cisplatin d
All Grades (%) Grade 3 (%) Grade 4 (%) All Grades (%) Grade 3 (%) Grade 4 (%)
Hematologic
Anemia 88 22 0 77 13 2
Neutropenia 88 36 28 87 20 56
Thrombocytopenia 81 39 16 45 8 5
RBC Transfusionsc 29 - - 21 - -
Platelet Transfusionse 3 - - 8 - -
Hepatic
Increased Alkaline Phosphatase 16 0 0 11 0 0
Increased ALT 6 0 0 12 0 0
Increased AST 3 0 0 11 0 0
Renal
Hematuria 22 0 0 10 0 0
Proteinuria 12 0 0 5 0 0
Increased BUN 6 0 0 4 0 0
Increased Creatinine 2 0 0 2 0 0

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on animal data and its mechanism of action, Gemcitabine for Injection can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on the use of Gemcitabine for Injection in pregnant women. In animal reproduction studies, gemcitabine was teratogenic, embryotoxic, and fetotoxic in mice and rabbits (see Data).

Advise pregnant women of the potential risk to a fetus [see Use in Special Populations (8.3)]. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20% respectively. Data Animal Data Gemcitabine is embryotoxic in mice.

Daily dosing of gemcitabine to pregnant mice increased the incidence of fetal malformation (cleft palate, incomplete ossification) at doses of 1.5 mg/kg/day [approximately 0.005 times the 1000 mg/m 2 clinical dose based on body surface area (BSA)]. Gemcitabine was embryotoxic and fetotoxic in rabbits. Daily dosing of gemcitabine to pregnant rabbits resulted in fetotoxicity (decreased fetal viability, reduced litter sizes, and developmental delays) and increased the incidence of fetal malformations (fused pulmonary artery, absence of gall bladder) at doses of 0.1 mg/kg/day (approximately 0.002 times the 1000 mg/m 2 clinical dose based on BSA).

Mechanism of action

12.1 Mechanism of Action Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary. Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabine diphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleoside triphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP.

Gemcitabine triphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration of dCTP by the action of the diphosphate enhances the incorporation of gemcitabine triphosphate into DNA (self-potentiation). After the gemcitabine nucleotide is incorporated into DNA, only one additional nucleotide is added to the growing DNA strands, which eventually results in the initiation of apoptotic cell death.

US FDA label

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The half-life of the terminal phase for gemcitabine triphosphate from mononuclear cells ranges from 1.7 to 19.4 hours.

Excretion Gemcitabine disposition was studied in 5 patients who received a single 1000 mg/m 2 of radiolabeled drug as a 30-minute infusion.

Gemcitabine (<10%) and the inactive uracil metabolite, 2′-deoxy-2′,2′-difluorouridine (dFdU) accounted for 99% of the excreted dose.

Differences in either clearance or volume of distribution based on patient characteristics or the duration of infusion result in changes in half-life and plasma concentrations.

Table 15 shows plasma clearance and half-life of gemcitabine following short infusions for typical patients by age and sex.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics The pharmacokinetics of gemcitabine were examined in 353 patients with various solid tumors. Pharmacokinetic parameters were derived using data from patients treated for varying durations of therapy given weekly with periodic rest weeks and using both short infusions (<70 minutes) and long infusions (70 to 285 minutes).

The total Gemcitabine for Injection dose varied from 500 mg/m 2 to 3600 mg/m 2. Distribution The volume of distribution was increased with infusion length. Volume of distribution of gemcitabine was 50 L/m 2 following infusions lasting <70 minutes. For long infusions, the volume of distribution rose to 370 L/m 2. Gemcitabine pharmacokinetics are linear and are described by a 2-compartment model.

Population pharmacokinetic analyses of combined single and multiple dose studies showed that the volume of distribution of gemcitabine was significantly influenced by duration of infusion and sex. Gemcitabine plasma protein binding is negligible. Elimination Metabolism The active metabolite, gemcitabine triphosphate, can be extracted from peripheral blood mononuclear cells.

The half-life of the terminal phase for gemcitabine triphosphate from mononuclear cells ranges from 1.7 to 19.4 hours. Excretion Gemcitabine disposition was studied in 5 patients who received a single 1000 mg/m 2 of radiolabeled drug as a 30-minute infusion. Within one week, 92% to 98% of the dose was recovered, almost entirely in the urine.

Gemcitabine (<10%) and the inactive uracil metabolite, 2′-deoxy-2′,2′-difluorouridine (dFdU) accounted for 99% of the excreted dose. The metabolite dFdU is also found in plasma. Specific Populations Geriatric Patients Clearance of gemcitabine was affected by age. The lower clearance in geriatric patients results in higher concentrations of gemcitabine for any given dose.

Differences in either clearance or volume of distribution based on patient characteristics or the duration of infusion result in changes in half-life and plasma concentrations. Table 15 shows plasma clearance and half-life of gemcitabine following short infusions for typical patients by age and sex. Table 15: Gemcitabine Clearance and Half-Life for the “Typical” Patient a Half-life for patients receiving a <70 minute infusion.

Age Clearance Men Clearance Women Half-Life a Men Half-Life a Women (L/hr/m 2) (L/hr/m 2) (min) (min) 29 92.2 69.4 42 49 45 75.7 57.0 48 57 65 55.1 41.5 61 73 79 40.7 30.7 79 94 Gemcitabine half-life for short infusions ranged from 42 to 94 minutes and for long infusions varied from 245 to 638 minutes, depending on age and sex, reflecting a greatly increased volume of distribution with longer infusions. Male and Female Patients Females have lower clearance and longer half-lives than male patients as described in Table 15.

Patients with Renal Impairment No clinical studies have been conducted with gemcitabine in patients with decreased renal function. Patients with Hepatic Impairment No clinical studies have been conducted with gemcitabine in patients with decreased hepatic function. Drug Interaction Studies When Gemcitabine for Injection (1250 mg/m 2 on Days 1 and 8) and cisplatin (75 mg/m 2 on Day 1) were administered in patients with NSCLC, the clearance of gemcitabine on Day 1 was 128 L/hr/m 2 and on Day 8 was 107 L/hr/m 2.

Data from patients with NSCLC demonstrate that Gemcitabine for Injection and carboplatin given in combination does not alter the pharmacokinetics of gemcitabine or carboplatin compared to administration of either single agent; however, due to wide confidence intervals and small sample size, interpatient variability may be observed. Data from metastatic breast cancer patients shows that Gemcitabine for Injection has little or no effect on the pharmacokinetics (clearance and half-life) of paclitaxel and paclitaxel has little or no effect on the pharmacokinetics of gemcitabine.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Gemcitabine 1 g Vial₱1,500.00–₱3,500.00Reference ₱1,700.00per vialDPRI procurement range
Gemcitabine 200 mg Vial₱450.00–₱695.00Reference ₱499.00per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Gemcitabine (as hydrochloride)
PNF listingInj.: 200 mg and 1 g vial (IV infusion)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. gemcitabine · Sagent Pharmaceuticals [US FDA-approved label, version 13, August 20, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44bcc16c-341d-49e8-a1c6-95d084667aca
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .